5:19 PM
 | 
Dec 16, 2011
 |  BC Extra  |  Top Story

FDA expects slow biosimilars ramp-up

FDA expects to receive only one or two biosimilar marketing applications through the beginning of 2014, Theresa Mullin, director of FDA's Office of Planning and Informatics, told...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >